| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0333102413480756 |
| P698 | PubMed publication ID | 23564209 |
| P50 | author | Peter J. Goadsby | Q51744546 |
| Michele Viana | Q60861584 | ||
| Armando A. Genazzani | Q39185102 | ||
| P2093 | author name string | Giuseppe Nappi | |
| Salvatore Terrazzino | |||
| P2860 | cites work | Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan | Q39427714 |
| The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients | Q43058226 | ||
| Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis | Q44341591 | ||
| Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. | Q45987869 | ||
| Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan | Q46738281 | ||
| Advances in pharmacological treatment of migraine | Q28192002 | ||
| Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials | Q34154647 | ||
| Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan | Q34205990 | ||
| Association study between clinical response to rizatriptan and some candidate genes | Q36332449 | ||
| Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials | Q36373560 | ||
| Almotriptan: meeting today's needs in acute migraine treatment | Q37021307 | ||
| Pathways to the best fit of triptans for migraine patients. | Q37247869 | ||
| Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention | Q39307543 | ||
| Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan | Q39348177 | ||
| Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. | Q39355111 | ||
| Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial | Q39365280 | ||
| Triptan nonresponder studies: implications for clinical practice | Q39370824 | ||
| Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study | Q39396690 | ||
| What do patients with migraine want from acute migraine treatment? | Q39408073 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 891-896 | |
| P577 | publication date | 2013-04-05 | |
| P1433 | published in | Cephalalgia | Q5063251 |
| P1476 | title | Triptan nonresponders: do they exist and who are they? | |
| P478 | volume | 33 |
| Q94460456 | A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication |
| Q40867528 | A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan |
| Q48226245 | Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache |
| Q90726206 | Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response |
| Q53207339 | Factors associated with frovatriptan response in patients with migraine: A prospective, observational study. |
| Q97527136 | Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme |
| Q92749141 | Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) |
| Q60960555 | Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study |
| Q92238062 | Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine |
| Q38195629 | Pharmacogenomics of episodic migraine: time has come for a step forward. |
| Q92319274 | Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine |
| Q99588832 | Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study |
| Q36176711 | Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation |
| Q55084349 | Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. |
| Q38176658 | The multitarget drug approach in migraine treatment: the new challenge to conquer |
| Q34109369 | Treatment adherence among new triptan users: a 2-year cohort study in Taiwan |
| Q39173843 | Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study |
| Q38608897 | Vagus Nerve Stimulation and Headache |
| Q40396310 | Variability of the characteristics of a migraine attack within patients |
Search more.